Crescita Therpeutc (CTX) AI Stock Analysis

• Market Cap: C$8.43M
• Dividend Yield: N/A
• Average Volume (3M): 12.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 26.79%
• EPS Growth: N/A
• Country: CA
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 18,613,937
• 10 Day Avg. Volume: 2,470
• 30 Day Avg. Volume: 12,630
• PEG Ratio: -0.09
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.57
• P/FCF Ratio: 7.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: C$0.50 ▲(4.17% Upside)

Crescita Therapeutics faces significant challenges with declining revenues and profitability issues, reflected in a low financial performance score. Technical analysis indicates a bearish trend with weak market momentum. Valuation concerns are highlighted by a negative P/E ratio and lack of dividend yield, further impacting the overall score.

Crescita Therpeutc Business Overview & Revenue Model

Company Description

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

How the Company Makes Money

Crescita Therapeutics generates revenue through a combination of product sales, licensing agreements, and collaborations with other pharmaceutical companies. Key revenue streams include the sale of its proprietary topical products in various markets, which are marketed directly or through partnerships with larger pharmaceutical firms. Additionally, CTX engages in licensing its drug delivery technology to other companies, receiving upfront payments and royalties from the sales of partnered products. Significant partnerships with research institutions and other biotech companies also contribute to its earnings by facilitating joint development projects and expanding its product portfolio.

Crescita Therpeutc Financial Statement Overview

Summary

Crescita Therapeutics shows mixed financial performance with declining revenues and profitability challenges. The balance sheet is stable with low leverage, but asset base contraction is concerning. Cash flow management has improved, yet inconsistencies remain. Overall, the company faces significant headwinds in revenue and profitability but maintains a stable financial position.

Income Statement

Crescita Therapeutics has experienced a declining revenue trend from 2022 to 2024, with total revenue decreasing by 16.8% from 2022 to 2023 and further by 11.2% from 2023 to 2024. The company has negative EBIT and net income margins, indicating challenges in managing operating expenses and generating profits. Gross profit margin fell from 55.98% in 2022 to 49.06% in 2024, showing pressure on profitability.

Balance Sheet

The company's balance sheet remains fairly stable, with a manageable debt-to-equity ratio of 0.05 in 2024, suggesting low financial leverage. However, stockholders' equity has decreased over the years. The equity ratio of 72.71% in 2024 reflects a solid capital structure. However, the decline in total assets from 2020 to 2024 indicates a contraction in the company's asset base.

Cash Flow

There has been a positive trend in operating cash flow from 2023 to 2024, improving free cash flow from negative to positive territory. The free cash flow to net income ratio is favorable, indicating efficient cash management despite net losses. However, fluctuations in free cash flow growth and operating cash flow indicate inconsistencies in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.27M	19.58M	17.52M	23.52M	16.77M	15.64M
Gross Profit	10.53M	9.61M	10.36M	13.18M	10.01M	11.27M
EBITDA	91.00K	-1.33M	45.00K	2.09M	598.00K	2.26M
Net Income	-1.33M	-2.75M	-1.99M	862.00K	-1.10M	37.00K
Balance Sheet
Total Assets	21.89M	21.78M	24.60M	28.48M	28.92M	26.83M
Cash, Cash Equivalents and Short-Term Investments	8.18M	9.27M	9.38M	8.24M	11.33M	14.28M
Total Debt	602.00K	834.00K	1.25M	1.61M	2.87M	1.23M
Total Liabilities	6.27M	5.95M	5.78M	7.39M	8.40M	5.70M
Stockholders Equity	15.61M	15.83M	18.82M	21.10M	20.53M	21.13M
Cash Flow
Free Cash Flow	-137.00K	1.54M	1.94M	-1.25M	-1.94M	5.55M
Operating Cash Flow	1.28M	2.73M	2.08M	-1.02M	-1.60M	5.61M
Investing Cash Flow	-1.34M	-2.02M	-133.00K	-290.00K	-846.00K	-59.00K
Financing Cash Flow	-801.00K	-861.00K	-782.00K	-1.85M	-500.00K	-476.00K

Crescita Therpeutc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CTX, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.47, and below the 200-day MA of 0.51, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CTX.

Crescita Therpeutc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MPH	55 Neutral	C$13.57M	-9.95	-7.15%	―	10.84%	48.57%
CTX	54 Neutral	C$8.43M	-6.56	2.83%	―	26.79%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RVV	46 Neutral	C$4.19M	-0.38	-583.18%	―	―	-84.51%
MVMD	35 Underperform	C$5.29M	―	-132.79%	―	-46.59%	9.48%
AQS	21 Underperform	C$663.17K	-0.81	―	―	192.96%	42.59%

Crescita Therpeutc Corporate Events

Crescita Therapeutics Reports Strong Q3 2025 Growth and Strategic Developments

Crescita Therapeutics reported significant financial growth in Q3 2025, with revenue and net income increases driven by its Manufacturing segment. The acquisition of assets from Laboratoire Provence-Canada Inc. and a new five-year supply agreement have bolstered Crescita’s recurring revenue and manufacturing capabilities. The company also regained rights to Pliaglis in several European and South American markets after terminating a licensing agreement with Croma Pharma GmbH, positioning Crescita to explore new partnerships.

The most recent analyst rating on (TSE:CTX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Crescita Therpeutc stock, see the TSE:CTX Stock Forecast page.

Crescita Therapeutics Reports Strong Q2 2025 Results and Strategic Developments

Crescita Therapeutics reported a strong financial performance for the second quarter of 2025, with significant year-over-year improvements in revenue, gross profit, and net income. The company successfully fulfilled key purchase orders and saw growth in its skincare segment. A mutual termination agreement with Croma Pharma GmbH added a substantial amount to its topline, and Crescita is now exploring new partnerships for its Pliaglis product in Europe. The company also repurchased shares under its Normal Course Issuer Bid, indicating confidence in its market position and future growth prospects.